pixantrone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antineoplastics; anthraquinone derivatives | 4330 | 144675-97-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an immunosuppressant; structure given in first source
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 10.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 17.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 13.40 hours | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.32 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 10, 2012 | EMA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01DB11 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D059005 | Topoisomerase II Inhibitors |
| MeSH PA | D059003 | Topoisomerase Inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Non-Hodgkin's lymphoma | indication | 118601006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.79 | Basic |
| pKa2 | 8.19 | Basic |
| pKa3 | 5.37 | Basic |
| pKa4 | 4.71 | Basic |
| pKa5 | 1.29 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D05522 | KEGG_DRUG |
| C0253355 | UMLSCUI |
| CHEBI:135945 | CHEBI |
| CHEMBL167731 | ChEMBL_ID |
| CHEMBL2103844 | ChEMBL_ID |
| DB06193 | DRUGBANK_ID |
| C086548 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7544 | IUPHAR_LIGAND_ID |
| 8260 | INN_ID |
| F5SXN2KNMR | UNII |
| 134019 | PUBCHEM_CID |
| 015628 | NDDF |
| 015629 | NDDF |
| 710295008 | SNOMEDCT_US |
| 144510-96-3 | SECONDARY_CAS_RN |
Pharmaceutical products:
None